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Abstract
Background:  Tocilizumab  is  an  IL-6  receptor-blocking  agent  proposed  for  the  treatment  of
severe COVID-19.  The  aim  of  this  systematic  review  was  to  describe  the  rationale  for  the  use  of
tocilizumab  for  the  treatment  of  COVID-19  and  to  summarize  the  available  evidence  regarding
its efficacy  and  safety.
Methods:  MEDLINE,  PubMed,  EMBASE,  pre-print  repositories  (bioRxiv  and  medRxiv)  and  two
trial Registries  were  searched  for  studies  on  the  use  of  tocilizumab  in  COVID-19  or  SARS-CoV-2
infection,  viral  pneumonia,  and/or  sepsis  until  20th  June  2020.
Results:  We  identified  3  indirect  pre-clinical  studies  and  28  clinical  studies  including  5776
patients with  COVID-19  (13  with  a  comparison  group,  15  single-arm).  To  date,  no  randomized
trials have  been  published.  We  retrieved  no  studies  at  low  risk  of  bias.  Forty-five  ongoing  studies
were retrieved  from  trial  registries.
Abbreviations: AIFA, Agenzia Italiana del Farmaco; ARDS, Acute respiratory distress syndrome; COVID-19, Coronavirus disease 2019; CPAP,
Continuous positive airway pressure; CRS, CAR-T cell-induced cytokine release syndrome; GCA, Giant cell arteritis; ICTRP, International Clin-
ical Trials Registry Platform; IDSA, Infectious Diseases Society of America; IMV, Invasive mechanical ventilation; NIH, U.S. National Institutes
of Health; NIV, Noninvasive mechanical ventilation; pJIA, Pediatric juvenile idiopathic arthritis; RA, Rheumatoid arthritis; SIMIT, Italian
Society of Infectious and Tropical disease; sJIA, Juvenile idiopathic arthritis; TNF, Tumor necrosis factor; WHO, World Health Organization.
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Conclusions:  There  is  insufficient  evidence  regarding  the  clinical  efficacy  and  safety  of
tocilizumab  in  patients  with  COVID-19.  Its  use  should  be  considered  experimental,  requiring
ethical approval  and  clinical  trial  oversight.
© 2020  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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he  search  for  the  holy  grail  of  medical  treatment  for
OVID-19  (Coronavirus  Disease-2019)  has  led  researchers
o  propose,  among  other  options,  the  use  of  IL-6  recep-
or  blocking  agents  for  treatment  of  symptomatic  patients.1
ith  a  death  toll  of  nearly  400.000  worldwide  and  nearly  7
illion  known  cases2,3 the  current  lack  of  targeted  effective
edication  and  ongoing  reliance  on  supportive  treatment
lone  remains  a  major  cause  of  concern.1
Patients  with  the  most  severe  COVID-19  symptoms  (i.e.
evere  lung  damage,  septic  shock  and  multiple  organ  fail-
re)  also  exhibit  what  seems  to  be  a  hyper-inflammatory
yndrome.4 Early  serology  analyses  identified  higher  IL-6
erum  levels  in  patients  with  severe  COVID-19  (particularly
on-survivors)  when  compared  to  patients  with  mild  and
oderate  disease.5,6 As  it  has  been  proposed  that  elevated
L-6  levels  may  be  associated  with  greater  disease  severity,
he  assumption  is  that  they  are  also  associated  with  worse
linical  outcomes7 and  vice  versa.  This  assumption  underlies
he  current  interest  in  anti-inflammatory  therapies  for  the
reatment  of  COVID-19.8
One  of  the  IL-6  receptor  blocking  agents  proposed  for
reatment  of  COVID-19,  tocilizumab,  was  introduced  in  the
arly  2000’s  for  treatment  of  autoimmune  disorders  such  as
efractory  rheumatoid  arthritis  and  systemic  juvenile  idio-
athic  arthritis  (sJIA)9,10 and  has  been  approved  by  the  FDA
ince  2017  for  treatment  of  the  cytokine  release  syndrome
CRS)  that  may  occur  following  some  forms  of  immunother-
py  (e.g.  CAR-T).11 The  aim  of  this  review  was  to  describe
he  rationale  and  summarize  the  available  evidence,  direct
nd  indirect,  regarding  the  use  of  tocilizumab  for  treatment
f  SARS-CoV-2  infection  and  to  identify  and  describe  ongoing
linical  trials  with  this  drug.
ethods
 preliminary  search  conducted  prior  to  formal  study  ini-
iation  suggested  the  evidence  on  the  topic  is  likely  to  be
imited,  and  yet  patients  are  already  receiving  the  drug,
aking  the  issue  urgent.  Therefore,  the  protocol  of  this
ystematic  review  was  not  registered.
ICO  questionPlease  cite  this  article  in  press  as:  Cortegiani  A,  et  al.  Pulmono
e  sought  information  regarding  the  use  of  tocilizumab  (I)
or  treatment  of  COVID-19,  SARS-CoV-2  infection,  viral  pneu-
onia,  and/or  sepsis  in  any  population  (adults  and  children)
r  laboratory  model  (P)  with  or  without  a  comparator  (C).  We
u
w
a
pimed  to  describe  any  treatment  outcome  whether  solicited
r  unsolicited  (O).
earch  methods  and  article/trial
nclusion/exclusion  criteria
e  conducted  a  systematic  search  of  the  MEDLINE,  PubMed
nd  EMBASE  databases  from  inception  to  20th  June  2020.
e  sought  pre-clinical  and  clinical  studies  addressing  the
se  of  tocilizumab  for  treating  COVID-19,  SARS-CoV-2  infec-
ion,  viral  pneumonia,  and/or  sepsis.  Our  search  included
he  keywords  ‘tocilizumab’,  ‘covid-19’,  ‘coronavirus’,  ‘sep-
is,  ‘pneumonia,  and  ‘viral  infection’  as  exact  phrases  and
 combination  of  subject  headings  according  to  databases
yntax.  We  also  searched  the  references  of  retrieved  papers
or  additional  potentially  relevant  papers.  In  order  to
nd  prepublication  manuscripts,  we  surveyed  the  pre-print
epositories  biorRxiv  and  medRxiv  from  inception  to  20th
une  2020  for  clinical  or  pre-clinical  studies  about  the  use  of
ocilizumab  in  COVID-19  or  SARS-CoV-2  infection,  viral  pneu-
onia,  and/or  sepsis.  No  language  restrictions  were  imposed
n  any  of  the  searches.  Finally,  to  identify  clinical  trials
tudying  treatment  with  tocilizumab  for  COVID-19,  SARS-
oV-2  infection,  viral  pneumonia,  and/or  sepsis,  we  sought
rials  registered  prior  to  20th  June  2020  in  the  Chinese  Clin-
cal  Trial  Registry  and  Clinicatrial.gov.  The  databases  and
he  trial  registries  were  all  screened  independently  and  in
uplicate  by  two  of  the  authors  (MI,  VG).
In  the  second  stage,  the  abstracts  of  all  potentially  rele-
ant  papers  and  pre-publication  manuscripts  were  screened
o  identify  relevant  papers  to  be  downloaded  in  full.  After
ownloading  potentially  relevant  articles,  case  reports,  case
eries  and  reviews  were  excluded.  Discrepancies  and  doubts
egarding  the  relevance  of  papers  downloaded  in  full  were
esolved  by  discussion  and  consensus  with  two  additional
uthors  (AC,  MG).
isk  of  bias  assessment
wo  of  the  authors  (AC,  MI)  assessed  the  risk  of  bias
RoB)  of  the  included  studies  independently  and  in  dupli-
ate.  Disagreements  over  RoB  were  resolved  by  consensus
r,  if  necessary,  adjudicated  by  a  third  author  (AG).  The
OBINS-I  tool  (Risk  Of  Bias  in  Non-randomized  Studies  of
nterventions)  was  used  for  nonrandomized  studies  with  a
omparison  group.12 The  Newcastle  Ottawa  Scale  (NOS)  wasl.  2020.  https://doi.org/10.1016/j.pulmoe.2020.07.003
sed  for  single-arm  nonrandomized  studies.13 The  domains
ere  rated  in  accordance  with  the  requirements  of  the
ssessment  tool  used,  with  the  lowest  score  achieved
redominating  as  accepted.  We  used  the  Risk-of-Bias  VISual-
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and  their  deaths  were  also  recorded  as  mortality.Figure  1  PRISMA  flow-chart.
The  figure  shows  the  PRISMA  flow-chart  with  inclusion/exclusio
ization  (robvis)  tool14 to  present  the  risk  of  bias  assessments
as  either  a  plot  or  a  table.
Results
The  initial  search  identified  2071  records  from  MEDLINE,
PubMed  and  EMBASE,  pre-print  repositories  and  other
sources.  After  screening  of  titles  and  abstracts,  removal
of  duplicates  and  evaluation  of  the  additional  sources
retrieved,  overall  31  published  peer-reviewed  papers  and
preprint  non  peer-reviewed  papers  were  included  (see  the
PRISMA  flow  diagram,  available  in  Fig.  1  for  the  study  selec-
tion  process).  Three  papers  described  preclinical  studies  and
28  papers  described  clinical  studies.  The  characteristics  of
the  clinical  studies  included  were  summarized  (see  Table  1).
In  addition,  forty-five  ongoing  clinical  studies  were  retrieved
from  the  trial  Registries.  These  too  were  tabulated  (see
Table  A1,  Appendix  A).Please  cite  this  article  in  press  as:  Cortegiani  A,  et  al.  Pulmono
Pre-clinical  studies  and  rationale
The  hypothetical  justification  for  treating  patients  with
tocilizumab  in  the  context  of  COVID-19  stems  from  indirect
n
acess  in  details.
ndings.  These  include  several  pre-clinical  studies  describ-
ng  a  beneficial  effect  in  cellular  and  murine  models  of  sepsis
nd  influenza.15--17
In  a  cell  model  of  sepsis  (Human  monocyte  cell  line  THP-
),  tocilizumab  reduced  the  expression  of  TNF  and  IL-10,
own-regulated  inflammasome  activation  (reduced  levels  of
LRP3  and  CASP1)  and  inhibited  monocyte  phagocytic  activ-
ty.  The  authors  of  the  study  suggested  that  if  suppressing
he  ‘cytokine  storm’  is  important  when  treating  sepsis,  these
ffects  may  be  beneficial.15
Tocilizumab  has  also  been  evaluated  in  a  murine  model
f  Influenza  A  virus  infection.  Mice  were  anesthetized,
ntubated,  and  infected  with  mouse-adapted  H1N1.  The
ocilizumab  treated  group  (8  mg/kg  24  h  before  infection)
nd  the  controls  were  compared.  Reduced  skeletal  mus-
le  weakness  (measured  as  digital  grip  strength),  preserved
uscle  weight  and  increased  short-term  and  long-term  mor-
ality  were  registered  in  the  treated  group,  in  comparison
ith  controls.  The  mice  manifesting  distress  were  sacrificed
16l.  2020.  https://doi.org/10.1016/j.pulmoe.2020.07.003
In  a  rat  model  of  sepsis-induced  acute  lung  and  kid-
ey  injury,  tocilizumab  (4−8  mg/kg)  reduced  mortality.  The
uthors  also  observed  normalization  of  persistently  high
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Table  1  Characteristics  of  the  included  studies.
Author  Study  type
(Country)
Population  (N)  Treatment  Comparison  Outcomes  Main  findings  Overall  risk  of
bias
Alattar  et  al.18 Single-centre
retrospective
observational
study  (Qatar)
Patients  with
severe
COVID-19
(n  =  25)
Median  of  tocilizumab
dose  1  mg/kg  (IQR,  1--3);
median  total  dose
5.7 mg/kg  (IQR,
4.8--9.5).  Median  time  to
treatment  1  day  (IQR,
1--3)  from  admission  to
ICU.
No  comparison  Alive  ICU
discharge  at
day  14;
ventilatory
support;
inflammatory
markers;
adverse  events
Nine  patients  (36%)  were
discharged  alive  from  ICU  by
day  14.  Of  the  remaining  16,
three  (12%)  patients  died  and
13  (52%)  were  still  in  ICU.
Twenty-three  (92%)  patients
experienced  adverse  events.
Poor  quality
score  (NOS)
Campochiaro
et al.19
Single-centre
prospective
observational
study  (Italy)
Patients  with
severe
COVID-19  and
hyperinflamma-
tion
(n  =  65)
Tocilizumab  i.v.  at
400  mg.  Second  dose
400  mg  after  24  h  in  case
of  respiratory  worsening
after  the  first  infusion.
(n  =  32)
Not  receiving
tocilizumab
(n  =  33)
Overall  survival
and  the
proportion  of
discharge  alive
from  hospital
or  decrease  of
at least  2
points  from
baseline  on  the
six-category
ordinal  scale  at
28 days;
adverse  events.
By  day  28:  16%  of  TCZ  group
compared  to  33%  of  standard
treatment  group  died
(p =  0.150).  63%  of  TCZ  group
compared  to  49%  of  standard
treatment  group  were
discharged  from  the  hospital
(p  =  0.32),  with  a  similar
median  time  to  discharge.
Clinical  improvement  in  69%  of
the TCZ  group  and  in  61%  of
the  standard  treatment  group,
p  =  0.61.  Serious  adverse
events  in  25%  of  the  TCZ  group
and in  27%  of  the  standard
treatment  group.  Bacteremia
in 13%  of  the  TCZ  group  and
12%  of  the  standard  treatment
group  (p  =  0.99).
Serious  risk  of
bias  (ROBINS-I)
Capra et  al.23 Single-centre
retrospective
observational
study  (Italy)
Hospitalized
patients  with
non  critical
respiratory
failure  and
COVID-19
(n  =  85)
Tocilizumab  400−800  mg
i.v.  or  324  mg  s.c.
administered  within  4
days  from  admission
(n  =  62)
Not  receiving
tocilizumab
admitted
earlier  than  4
days  before
tocilizumab
availability  in
the  centre
(n  =  23)
Survival  rate;
clinical
improvement;
infections
TCZ  group  had  significantly
greater  survival  rate  compared
to  control  (HR  for  death,
0.035;  95%  CI,  0.004−0.347;
p  =  0.004).  No  infections
related  to  tocilizumab  and  no
increased  levels  of  serum
procalcitonin.
Moderate  risk
of  bias
(ROBINS-I)
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Table  1  (Continued)
Author  Study  type
(Country)
Population  (N) Treatment Comparison  Outcomes  Main  findings Overall  risk  of
bias
Colaneri
et  al.24
Single-centre
retrospective
observational
study  (Italy)
Hospitalized
patients  with
COVID-19
(n  =  112)
Tocilizumab  i.v.  8  mg/kg
(up  to  a  maximum
800  mg  per  dose),
repeated  after  12  h  if  no
side effects  (n  =  21)
Not  receiving
tocilizumab
(n  =  91)
ICU  admission
and  7-day
mortality  rate;
clinical  and
laboratory
data;  adverse
events
No  adverse  event.  TCZ  did  not
significantly  affect  ICU
admission  (OR  0.11;  95%  CI
0.00--3.38;  p  =  0.22)  or  7-day
mortality  (OR  0.78;  95%  CI
0.06--9.34;  p  =  0.84)  compared
with  standard  care.  Analysis
performed  on  propensity  score
matched  cohort  (42  patients)
Moderate  risk
of  bias
(ROBINS-I)
Guaraldi
et al.22
Multicentre
retrospective
observational
study  (Italy)
Patients  with
severe
COVID-19
(n  =  544)
Tocilizumab  8  mg/kg  (up
800  mg)  twice,  12  h  apart
or  162  mg  in  two
simultaneous  doses,
(324  mg  in  total)  (n  =  179)
Not  receiving
tocilizumab
(n  =  365)
Composite  of
death  or
invasive
mechanical
ventilation
Tocilizumab  associated  with  a
reduced  risk  of  invasive
mechanical  ventilation  or
death  (adjusted  hazard  ratio
0·61,  95%  CI  0·40--0·92;
p =  0·020).
Moderate  risk
of  bias
(ROBINS-I)
24 (13%)  of  the  treated  were
diagnosed  with  new  infections
vs.  14  (4%)  of  the  controls
(p <  0·0001)
Kewan et  al.21 Single-centre
retrospective
observational
study  (USA)
Patients  with
severe
COVID-19
(n  =  51)
Tocilizumab  8  mg/kg  and
received  (up  to  400  mg)
single  administration
(n  =  28)
Not  receiving
tocilizumab
(n  =  23)
Live  discharge
from  hospital
without
worsening  or  at
least  2  points
decrease  in  a
six  point  scale
including  death
Clinical  improvement  at  21
days  in  treated  vs.  control:
76.5%  (95%  CI:  57.3--95.6)  vs.
79.4%  (95%  CI:  56.0--100)  and
67.9%  (95%  CI:  43.2--92.7)  vs.
61.9%  (95%  CI:  21.9--100)
among  mechanical  ventilated
patients  (p  =  0.3)
Serious  risk  of
bias  (ROBINS-I)
Luo et  al.28 Single-centre
retrospective
observational
study  (China)
Patients  with
COVID-19
(n  =  15)
TCZ  80−600  mg  per
time.  Five  (33.3%)
patients  received  two  or
more  TCZ  doses
No  comparison  Laboratory
data  and
clinical  course
3/15  (20%)  death;  2/15  (13%)
aggravation;  9/15  (60%)
stabilization;  1/15  (7%)
improvement
Poor  quality
score  (NOS)
Morena et  al.30 Single-centre
prospective
nonrandomized
study  (Italy)
Patients  with
severe  or
critical
COVID-19  and
high  IL-6  levels
(n  =  51)
Tocilizumab
intravenously  either  at
fixed  first  dose  of  400  mg
followed  by  400  mg  after
12 h  or  8  mg/kg  at  T0
followed  by  8  mg/kg
after  12  h  (in  patients
with  body  weight  ≥  60
Kg)
No  comparison  Mortality;
adverse  events;
clinical  course
30-day  mortality:  27%.  61%
discharged  and  6  still
hospitalized  at  last  follow-up
(median  34days  (IQR  32−37)).
Hepatic  enzymes  increased  of
at least  3  times  the  normal
values  in  29%,
thrombocytopenia  in  14%,
neutropenia  in  6%  and
cutaneous  rash  in  2%.
Bacteremia  in  14  patients
(27%).
Poor  quality
score  (NOS)
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Author  Study  type
(Country)
Population  (N)  Treatment  Comparison  Outcomes  Main  findings  Overall  risk  of
bias
Price  et  al.20 Single-centre
prospective
nonrandomized
observational
study  (USA)
Hospitalized
patients  with
confirmed
COVID-19
(n  =  153)
Tocilizumab  8  mg/kg  i.v.
(up  to  800  mg);  second
dose  if  elevated  body
mass  index
No  comparison  Survival  at  day
14;  adverse
events
87%  survival  at  day  14;  6
patients  had  neutropenia,  6
bacteremia
Poor  quality
score  (NOS)
Quartuccio
et al.25
Single-centre
retrospective
observational
study  (Italy)
Patients  with
COVID-19
(n  =  111)
Tocilizumab  8  mg/kg  i.v.
single  administration
(n  =  42)
Not  receiving
tocilizumab
(n  =  69)
Clinical  course;
laboratory
findings;
complications
TCZ  group  9.5%  mortality,  43%
experienced  bacterial
complications.
Serious  risk  of
bias  (ROBINS-I)
No  deaths  or  complication  in
the standard  care  group.
Sciascia et  al.26 Multicentre
prospective
single-arm
study  (Italy)
Patients  with
severe
COVID-19
(n  =  63)
Tocilizumab  i.v.  8  mg/kg
or s.c.  324  mg.  Single
additional  dose  allowed
within  24  h
No  comparison  Safety;
improvement
of  laboratory
and  respiratory
parameters
Mortality  at  day  14  was  11%
(7/63).  No  severe  or  moderate
adverse  events  related  to  TCZ.
No  significant  difference  in
mortality  between  different
routes  of  administration
Poor  quality
score  (NOS)
Toniati et  al.29 Single-centre
prospective
non-
randomized
study  (Italy)
Patients  with
COVID-19  and
respiratory
failure  (BCRSS
score  ≥3)
(n  =  100)
Tocilizumab  8  mg/kg
(max800  mg)  two
consecutive  i.v.  infusions
12  h  apart.  A  third
infusion,  24  h  apart  from
the second  was  allowed
No  comparison  Clinical  and
laboratory  data
at  day  10;
adverse  events
At  24−72  h  after  TCZ,  58%  had
clinical  improvement,  37%
stabilized  and  5%  worsened  (of
whom  4%  died).  At  day  10,  77%
improved  or  stabilized  and  23%
worsened  (of  whom  20%  died).
Two  patients  developed  septic
shock  and  died,  one  had
gastrointestinal  perforation
requiring  urgent  surgery
Poor  quality
score  (NOS)
Xu et  al.27 Multicentre
retrospective
observational
study  (China)
Patients  with
severe  or
critical
COVID-19
(n  =  21)
Tocilizumab  first  dose
4--8 mg/kg
(recommended  dose
400  mg  through  an  i.v.
drip  up  to  a  maximum  of
800  mg).
No  comparison  Clinical
improvement;
adverse  events
No  adverse  reactions  observed.
All  patients  discharged  on
average  15.1  day  after
tocilizumab.  By  day  5  after
TCZ,  75.0%  of  patients  had
lower  oxygen  intake
Poor  quality
score  (NOS)
In case  of  fever  within
12  h,  single  additional
dose
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(Continued)
Author  Study  type
(Country)
Population  (N) Treatment Comparison  Outcomes  Main  findings Overall  risk  of
bias
Pre-print  not  peer  reviewed  studies
Fomina  et  al.37 Single-centre
retrospective
observational
study  (Russia)
Hospitalized
patients  with
COVID-19
(n  =  89)
Tocilizumab  400  mg No  comparison Clinical  course 63/72  not  mechanically
ventilated  patients  were
discharged,  1/72  died,  8/72
remained  in  hospital;  10/17
mechanically  ventilated
patients  died  and  7/10  remain
in hospital
Poor  quality
score  (NOS)
Gorgolas
et al.36
Single-centre
retrospective
observational
study  (Spain)
Hospitalized
patients  with
COVID-19
(n  =  186)
Tocilizumab  single  dose
of  400−600  mg  (16
received  two  doses  and  1
received  three  doses)
No  comparison Intubation  or
death  after
24  h  from
administration
51  patients  were  intubated  or
dead  at  day  15;  19  patients
needed  intubation  (of  whom  4
died)  and  36  died  (32  of  whom
were  not  intubated).  11  (5·9%)
patients  had  serious  adverse
reactions,  13  cases  (6·3%)  of
secondary  acquired  infections
Poor  quality
score  (NOS)
Ip et  al.31 Multicentre,
retrospective,
observational,
study  (USA)
ICU  patients
with  COVID-19
(n  =  547)
Tocilizumab:  400  mg
(96%),  followed  by
800  mg  (1%),  8  mg/kg
(1%),  4  mg/kg  (1%),  and
missing  dosing
(1%).(n  =  134)
Not  receiving
tocilizumab
(n  =  413)
Mortality;
adverse  events
Secondary  bacteremia  in  11%
of  the  non-treated  group,  13%
of  the  treated.  Secondary
pneumonia  in  6%  of  the
non-treated  group,  9%  of  the
treated.  Propensity  modeling
showed  a  trend  association
between  survival  and
tocilizumab  (HR,  0.76  [95%  CI,
0.57−1.00]).  The  unadjusted
30-day  mortality  favored
tocilizumab  (46%  vs.  56%)
Moderate  risk
of  bias
(ROBINS-I)
Kimmig et  al.32 Single-centre
nonrandomized
observational
study  (USA)
ICU  patients
with  critical
COVID-19
(n  =  60)
400  mg  flat  dosing  of
tocilizumab  with
possible  redosing  based
on clinical  response
(n  =  28)
Not  receiving
tocilizumab(n  =  32)
Bacterial  and
fungal
infections
TCZ  associated  with  higher
incidence  of  secondary
bacterial  infections  (64.3%  vs.
31.3%  p  =  0.010).  In  a  logistic
regression  model,  TCZ  was
independently  associated  with
secondary  bacterial  infections
(OR  3.96  (95%  CI
1.351−11.607),  p  =  0.033)
Serious  risk  of
bias  (ROBINS-I)
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(Country)
Population  (N)  Treatment  Comparison  Outcomes  Main  findings  Overall  risk  of
bias
Martinez-Sanz
et  al. 33
Multicentre
retrospective
observational
study  (Spain)
Hospitalized
patients  with
COVID-19
(n  =  1229)
Tocilizumab  median  dose
600  mg  (IQR
600--800  mg).  First  dose
at a  median  time  of  4
(IQR  3--5)  days  (n  =  260)
Not  receiving
tocilizumab
(n  =  969)
Time  to  death;
composite
including  ICU
admission  or
death
Tocilizumab  associated  with
higher  risk  of  death  (HR  1.53,
95% CI  1.20--1.96,  p  =  0.001)
and  ICU/death  (HR  1.77,  95%  CI
1.41--2.22,  p  <  0.001).The
effect  disappeared  in  the
adjusted  analyses
Moderate  risk
of  bias
(ROBINS-I)
Moreno-Garcia
et al.45
Single-centre
retrospective
observational
study  (Spain)
Non-ICU
patients  with
COVID-19
(n  =  171)
Tocilizumab  400  mg/24  h
iv for  patients  with
≤75  kg  and  600  mg/24  h
iv for  those  with  >75  kg.
Up to  3  doses  (12  h
apart)  if  partial  response
(n  =  77)
Not  receiving
tocilizumab
(n  =  94)
Composite  of
ICU  admission
or  death
Tocilizumab  group  had
significantly  less  ICU  admissions
(10.3%  vs.  195  27.6%,  P  =  0.005)
and  less  invasive  ventilation  (0
vs 13.8%,  P  =  0.001).  Findings
confirmed  at  propensity  score
matched  analysis  (OR:  0.03,  CI
95%:  0.007−0.1,  P  =  0.0001)
Moderate  risk
of  bias
(ROBINS-I)
Perrone et  al.44 Multicentre,
open-label
trial,  including
a  single-arm
phase  2  study
(Italy)
Hospitalized
patients  with
COVID-19
(n  =  1221)
Tocilizumab  8  mg/kg  (up
to  800  mg).  Second  dose
allowed  after  12  h,  if  not
recovered
No  comparison  Lethality  rates
at  day  14  and
day  30  days;
adverse  events
In  phase  2,  lethality  was  18.4%
(97.5%CI:  13.6−24.0,  P  =  0.52)
and  22.4%  (97.5%CI:
17.2−28.3,  P  <  0.001)  at  14  and
30 days.  Lower  rates  (15.6%
and  20.0%)  among  the  treated
(mITT,  n  =  708).
Poor  quality
score  (NOS)
Petrak et  al.35 Multicentre
retrospective
observational
study  (USA)
Hospitalized
patients  with
COVID-19
(n  =  145)
135  patients  received
4 mg/kg  (up  to  400  mg),
5  received  a  single  dose
of  600  mg  and  4  a  dose
of  800  mg.  Early
administration  (<1  day)
or  delayed  (>1  day)
No  comparison  Mortality;  LOS;
discharge
48.3%  discharged  and  29.3%
expired.  For  each  additional
day  that  the  tocilizumab  dose
is  delayed  from  admission,  the
odds  of  requiring  MV  increase
by  21%,  holding  all  other
covariates  constant  (95%  CI:
[1.08,  1.38],  p  =  0.002).
Poor  quality
score  (NOS)
Ramaswamy
et al.40
Multicentre
retrospective
observational
study  (USA)
Hospitalized
patients  with
COVID-19
(n  =  86)
Tocilizumab  dosed  at
either  400  mg  fixed  dose
or 8  mg/kg  (up  to
800  mg)  (n  =  21)
Not  receiving
tocilizumab
(n  =  65)
In-hospital
mortality
Reduced  risk  of  inpatient  death
in  the  treated  (HR  0.25;  95%  CI
0.07−0.90,  Cox  model).
Association  confirmed  in  the
treatment  effects  model  (RR
0.472;  95%  CI  0.449−0.497).
Moderate  risk
of  bias
(ROBINS-I)
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Author  Study  type
(Country)
Population  (N) Treatment Comparison  Outcomes  Main  findings Overall  risk  of
bias
Rimland
et  al.39
Single-centre
retrospective
observational
study  (USA)
Hospitalized
patients  with
COVID-19
(n  =  11)
Tocilizumab  median
dosage  7.9  mg/kg  (IQR
5.8−8.1),  median  time
to administration:  one
day (IQR  1−4)  from
admission  and  nine  days
(IQR  7−14)  after
symptom  onset
No  comparison Clinical  course Mortality  27%;  45%  remained  in
ICU on  mechanical  ventilation,
receiving  vasopressors  or
hemodialysis;  9%  were
transferred  from  the  ICU  to
floor  and  weaned  to  room  air;
18%  were  discharged  home
without  oxygen;  64%  had
minimally  elevated  liver
function  tests.  Two  patients
were  diagnosed  with  ileus  and
two  with  bacterial  pneumonia.
Poor  quality
score  (NOS)
No serious  adverse  events.
Rossi et  al.34 Single-centre
retrospective
observational
study  (France)
Patients  with
severe
COVID-19
(n  =  246)
Tocilizumab  400  mg
single  dose  (n  =  106)
Not  receiving
tocilizumab
(n  =  140)
Composite  of
all-cause
mortality  and
invasive
mechanical
ventilation
Tocilizumab  associated  with
fewer  primary  outcomes  47
(HR  =  0.49  (95%  CI  0.3−0.81),  p
value  =  0.005)  in  the  matched
cohort  (n  =  168),  and  full
cohort  (adjusted  HR  =  0.26  50
(95CI0.135−0.51,  p  =  0.0001),
confirmed  by  IPSW  analysis
(p  <  0.0001)
Moderate  risk
of  bias
(ROBINS-I)
Roumier
et al.38
Single-centre
nonrandomized
observational
study  (France)
Patients  with
severe
COVID-19  and
inflammatory
markers  (n  =  59)
8  mg/kg  at  the  discretion
of  treating  physicians,
renewable  once  in  case
of  insufficient  response
to  therapy  (n  =  30)
Not  receiving
tocilizumab
(n  =  29)
Clinical  course  TCZ  significantly  reduced  the
need  for  mechanical
ventilation  (weighted  OR:  0.42;
95%CI[0,20−0,89];  p  =  0,025).
Unadjusted  analysis  showed  a
reduction  of  mortality  (OR:
0.25  95%CI  [0.05−0.95],
p =  0.04),  statistical
significance  disappeared  after
weighted  analysis.
Moderate  risk
of  bias
(ROBINS-I)
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Sánchez-
Montalvá
et  al.43
Single-centre
prospective
and
retrospective
observational
study  (Spain)
Patients  with
severe
COVID-19  and
high  IL-6
(n  =  82)
Patients  over  75  kg
received  600  mg,
otherwise  400  mg.  A
second  dose  was
considered  in  case  of
poor  early  response
No  comparison  Mortality  at  7
days  after
tocilizumab
administration;
admission  to
the  ICU;
development  of
ARDS  and
respiratory
failure
41.5%  had  been  discharged,
26.8%  had  died,  17.1%  were  in
ICU,  11.0%  in  medical  wards,
3.7%  had  been  transferred  to
another  institution.  By  7-day
follow-up,  the  mortality  rate
was  4.0%  per  person-day  (95%
confidence  interval  [CI],
2.4%--6.2%)  by  Kaplan-Meier
analysis.  No  adverse  events
attributed  to  tocilizumab.
Poor  quality
score  (NOS)
Somers et  al.41 Single-centre
retrospective
observational
study  (USA)
Patients  with
severe
COVID-19  under
mechanical
ventilation
(n  =  154)
Tocilizumab  8  mg/kg
(maximum  800  mg);
additional  doses
discouraged  (n  =  78)
Not  receiving
tocilizumab
(n  =  76)
Survival
probability
post-
intubation;
ordinal  illness
severity  scale
integrating
superinfections
TCZ  associated  with  adjusted
lower  hazard  of  death  at
multiple  analyses  [Model  A:  HR
0.54  (95%  CI  0.29,  1.00)],
[Model  B:  n  =  116,  HR  0.55  (95%
CI 0.33,  0.90);  [Model  C:  HR
0.54  (0.35,  0.84)];  TCZ  treated
patients  were  more  than  twice
as  likely  to  develop  a
superinfection  than  untreated
controls  (54%  vs.  26%;
p <  0.001)
Moderate  risk
of  bias
(ROBINS-I)
Wadud et  al.42 Single-centre
retrospective
observational
study  (USA)
Hospitalized
patients  with
COVID-19
(n  =  94)
Tocilizumab  (n  =  44)  Not  receiving
tocilizumab
(n  =  50)
Length  of  stay;
length  of
ventilation;
mortality;
survival  and
discharge
(home,  rehab,
transfer  to
outside  facility)
Length  of  stay  was  longer,  in
the  TCZ  group.  Survival  rate
48%  in  the  control  group  vs
61.36%  in  patients  receiving
TCZ  (p  <  0.00001)
Serious  risk  of
bias  (ROBINS-I)
The table shows the main characteristics of the included studies.
ARDS, acute respiratory distress syndrome; BCRSS, Brescia COVID-19 Respiratory Severity Scale; CI, confidence interval; COVID-19, coronavirus disease 2019; HR, hazard ratio; ICU, intensive
care unit; IQR, interquartile range; mITT, modified intention to treat; OR, Odds ratio; SARS, severe acute respiratory syndrome; TCZ, tocilizumab; USA, United States of America.
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Rationale  and  Evidence  on  the  use  of  Tocilizumab  in  COVID-
serum  levels  of  IL-6  in  septic  rats  after  treatment  with
tocilizumab  and  improved  lung  wet/dry  weight  ratio  and
total  protein  content  in  the  treatment  group,  in  comparison
with  the  sham  group.17
Clinical  studies
We  retrieved  13  published  clinical  studies18--30 and  15  pre-
print  (i.e.  pre  peer  review)  clinical  studies,31--45 respectively
evaluating  1396  and  4380  patients,  for  a  total  of  5776
patients.  The  main  characteristics  of  the  included  clinical
studies  are  presented  in  Table  1.  Only  three  peer  reviewed
papers22,26,27 and  five  prepublications31,33,35,40,44 were  mul-
ticenter  studies.  Thirteen  studies  included  more  than  100
patients,  but  in  these  studies  the  number  of  patients  receiv-
ing  tocilizumab  was  not  large.  One  published  trial  included
112  patients  but  only  one  in  five  patients  (n  =  21)  received
tocilizumab.24 Another  published  trial  included  111  patients
among  whom  less  than  half  (n  =  49)  were  treated.25 One  pre-
publication  included  547  patients  of  which  a  third  (n  =  134)
were  treated31 and  another  included  1229  patients  of  which
260  received  tocilizumab.33 Seven  of  the  13  published  papers
and  six  of  the  15  prepublications  presented  no  comparator.
The  risk  of  bias  assessments  are  shown  in  Fig.  2  (nonran-
domized  studies  with  comparison)  and  in  Appendix  A,  Table
A2  (nonrandomized  single-arm  studies).  Ten  studies  were  at
moderate  and  five  at  serious  risk  of  bias  (ROBINS-I);  thirteen
studies  were  judged  to  be  of  ‘‘poor  quality’’  (NOS).  None  of
the  studies  were  assessed  as  having  a  low  risk  of  bias.
Discussion
The  mechanism  of  action  and  pharmacological
properties  of  tocilizumab
Tocilizumab  is  a  humanized  monoclonal  antibody  capable
of  interfering  with  the  IL-6  soluble  and  membrane  binding
site  of  the  receptor  (IL-6R),  thereby  blocking  the  assem-
bling  of  the  activated  complex  with  the  transmembrane
protein  (gp130-IL-6-sILr).  Tocilizumab  is  also  able  to  block
IL-6  trans-signaling46 which  is  strongly  related  to  the  pro-
inflammatory  effects  of  IL-6  (e.g.  release  of  acute  phase
proteins).  Tocilizumab  has  a  non-linear  pharmacokinetic
profile,  with  a  dose-response  curve  that  plateaus  at  an
approximate  dose  of  800  mg.46 The  half-life  of  tocilizumab
is  dose-dependent  and  comparable  to  the  half-life  of  IgG1.47
Interleukin-6  (IL-6)  and  COVID-19
IL-6  is  a  pleiotropic  cytokine  secreted  by  neutrophils,  mono-
cytes  and  macrophages  and  involved  in  the  inflammatory
response.  It  has  a  soluble  (sIL-6R)  and  a  membrane  bind-
ing  site  (mIL-6R),  constituting  its  receptors.  IL-6  can  bind
its  mIL-6R  at  low  doses  or,  at  higher  doses,  its  sIL-6R
(trans-signaling),  creating  the  activated  complex  with  gp130
protein.48 Signaling  is  mediated  by  Janus  kinases  (JAK)  andPlease  cite  this  article  in  press  as:  Cortegiani  A,  et  al.  Pulmono
Ras/mitogen-activated  protein  kinase  (MAPK)/NF-B-IL-6.48
IL-6  promotes  B  and  T  cells  differentiation,  acute  phase
protein  production  and  osteoclast  activation.46 High  lev-
els  of  IL-6  have  been  listed  among  the  main  features  of
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ytokine  storm  and  cytokine  release  syndrome  (CRS),  both
f  which  are  characterized  by  an  exaggerated  release  of
ro-inflammatory  cytokines  and  potentially  life-threatening
ultiorgan  damage.48 IL-6  also  seems  to  be  involved,
hrough  these  mechanisms,  in  the  pathophysiology  of  COVID-
9,  especially  in  the  most  severe  forms  of  the  disease.5,6,49,50
urthermore,  elevated  levels  of  IL-6  have  been  associ-
ted  with  a  hypercoagulable  state  in  both  animals  and
umans,51,52 and  coagulopathy  is  another  characteristic  of
atients  with  COVID-19  at  high  risk  of  death.53
vidence  on  efficacy  and  safety  of  tocilizumab  for
OVID-19
he  current  systematic  review  shows  that  although  indi-
ect  preclinical  data  suggests  rationale  for  using  tocilizumab
nd  observational  studies  suggest  that  treatment  with
ocilizumab  may  be  associated  with  more  favorable  out-
omes  compared  to  standard  care  in  patients  with  severe
r  critical  COVID-19,  up  till  now  no  RCTs  have  been  pub-
ished  or  made  available  pre-print  regarding  either  the
ffectiveness  or  the  safety  of  tocilizumab  in  the  context  of
OVID-19.
The  effects  of  tocilizumab  against  IL-6  related  pro-
nflammatory  and  pro-coagulant  status53 partially  explain
ts  potential  role  in  COVID-19.54 However,  it  is  worth
emembering  that  there  is  yet  no  evidence  that  sup-
ressing  the  physiological  inflammatory  response  to
he  virus  is  indeed  beneficial.  Previous  experience
ith  pharmaceutic  inflammatory  response  modulation  in
atients  with  ARDS55 and  sepsis56 have  been  notoriously
nsuccessful.
Several  observational  studies  have  examined  whether
ocilizumab  has  any  effect  in  patients  with  COVID-19.
lthough  many  of  the  patients  included  in  these  studies
ad  severe  or  critical  disease  and  many  were  admitted  to
CUs,  drawing  conclusions  from  the  findings  of  these  stud-
es  is  a  leap  of  faith,  given  that  most  had  small  sample
izes  and  high  or  moderate  risk  of  bias,  mostly  due  to  con-
ounding.  The  identified  studies  also  varied  in  dosing  (single
r  double),  and  drug  availability  issues  emerged  in  some
entres,  which  may  have  influenced  both  sample  sizes  and
tudy  designs.  Finally,  the  literature  suggests  the  presence
f  two  phases  in  the  pathophysiology  of  COVID-19.  An  early
hase  characterized  by  a  high  viral  load  and  limited  sys-
emic  impairment,  and  a  late  phase,  with  elevated  cytokine
evels  and  a  hyperinflammatory  state.4 Regarding  the  tim-
ng  of  drug  administration,  that  could  therefore  potentially
etermine  treatment  outcomes,  a  pre-print  study  eval-
ated  the  effect  of  early  vs  late  administration  of  the
rug  on  the  outcomes,  but  the  association  remains  unclear
nd  understudied.35 The  authors  found  that  for  each  addi-
ional  day  of  delay  from  the  admission  to  tocilizumab
dministration,  the  odds  of  receiving  mechanical  ventila-
ion  independently  increase  by  21%  (95%  CI:  [1.08,  1.38],
 =  0.002).35
Clinical  studies  on  patients  with  COVID-19  have  alsol.  2020.  https://doi.org/10.1016/j.pulmoe.2020.07.003
voked  some  safety  concerns.  The  risk  of  secondary
nfection  complications  is  unclear.  Among  the  stud-
es  with  a  comparison  group,  six  found  a higher  rate
f  infections  among  treated,  compared  to  untreated,
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Figure  2  Risk  of  bias  of  nonrandomized  studies  with  comparison  groups.
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mhe risk  of  bias  of  the  included  nonrandomized  studies  with  co
as assessed  using  Risk  of  Bias  in  Non-randomized  Studies  of  In
atients.19,22,25,31,32,41 Hepatotoxic  effects,  neutro-  and
hrombocytopenia  and  intestinal  perforation  have  also  been
escribed.57--59 This  is  worrying,  particularly  given  that  data
rom  a  clinical  study  promoted  by  the  Italian  agency  for
edicines  (Agenzia  Nazionale  del  Farmaco  - AIFA)  suggestsPlease  cite  this  article  in  press  as:  Cortegiani  A,  et  al.  Pulmono
o  significant  benefit  in  terms  of  either  mortality  (3.3%
s.  3.2%)  or  ICU  admission  (10.0%  vs  7.9%)  in  patients  not
equiring  mechanical  respiratory  support,  when  treated  with
ocilizumab  vs.  controls.60
a
l
w
Trison  groups  is  reported  per  single  study  and  per  domain.  RoB
ntions,  as  appropriate.
ecommendations  ad  ongoing  studies
everal  clinical  practice  guidelines  already  include
ocilizumab  as  a  therapeutic  option  for  COVID-19.  The
ost  recent  Chinese  guideline61 suggests  tocilizumab,  atl.  2020.  https://doi.org/10.1016/j.pulmoe.2020.07.003
 dose  of  4−8  mg/kg,  for  patients  with  extensive  lung
esions  and  for  severe  cases  with  increased  levels  of  IL-6  or
ith  complications.61 The  Italian  Society  of  Infectious  and
ropical  disease  (SIMIT  -  Lombardy  section),62 recommends
 IN+Model
19  
C
N
A
A
t
w
i
m
m
A
N
A
S
f
1
RARTICLEPULMOE-1521; No. of Pages 15
Rationale  and  Evidence  on  the  use  of  Tocilizumab  in  COVID-
selection  of  patients  who  have  recovered  from  the  initial
high  viral  load  (i.e.  afebrile  from  >72  h  or  with  symptoms
for  >7  days),  those  with  high  IL-6  levels  (>40  pg/mL),
those  with  increasing  levels  of  D-dimer,  C-reactive  protein,
ferritin  or  fibrinogen  levels  and  those  needing  ventilation
support  (CPAP,  NIV  or  IMV)  for  treatment  with  tocilizumab.
However,  both  the  ‘Surviving  Sepsis  Campaign:  Guidelines
on  the  Management  of  Critically  Ill  Adults  with  Coronavirus
Disease  2019  (COVID-19)  and  the  U.S.  National  Institutes
of  Health  (NIH)  state  that  the  evidence  does  not  suffice  to
issue  recommendations  regarding  the  use  of  tocilizumab
for  COVID-19.63,64 The  World  Health  Organization  (WHO)65
and  the  Infectious  Diseases  Society  of  America  (IDSA)66 both
recommend  that  tocilizumab  only  be  administered  within
the  context  of  a  clinical  trial.
Our  search  identified  45  registered  ongoing  trials,  includ-
ing  18  multicentre  randomized  trials  in  several  countries
across  4 continents.  The  details  of  the  studies  underway  are
provided  in  Appendix  A  (Table  A1).  The  results  of  these  trials
will  hopefully  provide  sufficient  data  regarding  the  role  of
tocilizumab  in  the  context  of  COVID-19.
Conclusion
Although  basic  science  suggests  rationale  for  administra-
tion  of  IL-6  receptor  antagonists  to  patients  with  COVID-19,
the  clinical  evidence  regarding  the  efficacy  and  safety  of
tocilizumab  for  COVID-19  remains  observational  only  and  is
methodologically  flawed.  As  concerns  have  also  been  raised
regarding  the  possibility  of  secondary  infection,  the  use  of
this  drug  should  be  limited  to  the  context  of  a  clinical  trial
and  accompanied  by  ethical  committee  approval  and/or
informed  consent,  as  well  as  appropriate  monitoring  for  side
effects.
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